These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2900622)

  • 1. Somatostatin and neuropeptide Y concentrations in pathologically graded cases of Huntington's disease.
    Beal MF; Mazurek MF; Ellison DW; Swartz KJ; McGarvey U; Bird ED; Martin JB
    Ann Neurol; 1988 Jun; 23(6):562-9. PubMed ID: 2900622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of somatostatin and neuropeptide Y distribution in monkey brain.
    Beal MF; Mazurek MF; Martin JB
    Brain Res; 1987 Mar; 405(2):213-9. PubMed ID: 3567602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential sparing of somatostatin-neuropeptide Y and cholinergic neurons following striatal excitotoxin lesions.
    Beal MF; Kowall NW; Swartz KJ; Ferrante RJ; Martin JB
    Synapse; 1989; 3(1):38-47. PubMed ID: 2563916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cortical peptide changes in Huntington's disease may be independent of striatal degeneration.
    Mazurek MF; Garside S; Beal MF
    Ann Neurol; 1997 Apr; 41(4):540-7. PubMed ID: 9124812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin and neuropeptide Y immunoreactivity in Parkinson's disease dementia with Alzheimer's changes.
    Beal MF; Clevens RA; Mazurek MF
    Synapse; 1988; 2(4):463-7. PubMed ID: 2903567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Widespread reduction of somatostatin-like immunoreactivity in the cerebral cortex in Alzheimer's disease.
    Beal MF; Mazurek MF; Svendsen CN; Bird ED; Martin JB
    Ann Neurol; 1986 Oct; 20(4):489-95. PubMed ID: 3789664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of regional somatostatin and neuropeptide Y distribution in rat striatum and brain.
    Beal MF; Chattha GK; Martin JB
    Brain Res; 1986 Jul; 377(2):240-5. PubMed ID: 3755369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurements of somatostatin and neuropeptide Y in the visual cortex of monocularly deprived rats.
    McDonald JK; Parnavelas JG; Davies SW; Cavanagh ME
    Exp Neurol; 1993 Oct; 123(2):216-21. PubMed ID: 8104819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Degeneration of pyramidal projection neurons in Huntington's disease cortex.
    Cudkowicz M; Kowall NW
    Ann Neurol; 1990 Feb; 27(2):200-4. PubMed ID: 2138444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cortical somatostatin, neuropeptide Y, and NADPH diaphorase neurons: normal anatomy and alterations in Alzheimer's disease.
    Kowall NW; Beal MF
    Ann Neurol; 1988 Feb; 23(2):105-14. PubMed ID: 2897822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The regional distribution of somatostatin and neuropeptide Y in control and Alzheimer's disease striatum.
    Beal MF; Mazurek MF; McKee MA
    Neurosci Lett; 1987 Aug; 79(1-2):201-6. PubMed ID: 2890123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid.
    Beal MF; Kowall NW; Ellison DW; Mazurek MF; Swartz KJ; Martin JB
    Nature; 1986 May 8-14; 321(6066):168-71. PubMed ID: 2422561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cortical lesion of Huntington's disease: further neurochemical characterization, and reproduction of some of the histological and neurochemical features by N-methyl-D-aspartate lesions of rat cortex.
    Storey E; Kowall NW; Finn SF; Mazurek MF; Beal MF
    Ann Neurol; 1992 Oct; 32(4):526-34. PubMed ID: 1280937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased neuronal nitric oxide synthase messenger RNA and somatostatin messenger RNA in the striatum of Huntington's disease.
    Norris PJ; Waldvogel HJ; Faull RL; Love DR; Emson PC
    Neuroscience; 1996 Jun; 72(4):1037-47. PubMed ID: 8735228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropeptides in neurological disease.
    Beal MF; Martin JB
    Ann Neurol; 1986 Nov; 20(5):547-65. PubMed ID: 2947536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization.
    Ferrante RJ; Kowall NW; Cipolloni PB; Storey E; Beal MF
    Exp Neurol; 1993 Jan; 119(1):46-71. PubMed ID: 8432351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A detailed examination of substance P in pathologically graded cases of Huntington's disease.
    Beal MF; Ellison DW; Mazurek MF; Swartz KJ; Malloy JR; Bird ED; Martin JB
    J Neurol Sci; 1988 Mar; 84(1):51-61. PubMed ID: 2452859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A quantitative assessment of somatostatin-like and neuropeptide Y-like immunostained cells in the frontal and temporal cortex of patients with Alzheimer's disease.
    Davies CA; Morroll DR; Prinja D; Mann DM; Gibbs A
    J Neurol Sci; 1990 Apr; 96(1):59-73. PubMed ID: 1972185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional specificity of brain atrophy in Huntington's disease.
    Halliday GM; McRitchie DA; Macdonald V; Double KL; Trent RJ; McCusker E
    Exp Neurol; 1998 Dec; 154(2):663-72. PubMed ID: 9878201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin and neuropeptide Y are unaltered in the amygdala in schizophrenia.
    Beal MF; Svendsen CN; Bird ED; Martin JB
    Neurochem Pathol; 1987 Jun; 6(3):169-76. PubMed ID: 2888067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.